Harry Wilcox Joins Flagship Ventures as CFO and Partner

Harry Wilcox Joins Flagship Ventures as CFO and Partner

October 23, 2006

Harry Wilcox has joined Flagship Ventures as CFO and Partner. Harry will take over from Cheryl Goyette who will be leaving us during November to join a newly formed venture firm as their CFO. We are thankful for the many contributions made by Cheryl in managing our partnership finance activities over the last 8 years and look forward to continuing to excel in this area under the able leadership of Harry.

Ensemble Therapeutics Corporation

The Leukemia & Lymphoma Society and Ensemble Discovery Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers

The Leukemia & Lymphoma Society and Ensemble Discovery Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers

November 13, 2006

First initiative under the Society’s new Therapy Acceleration Program, designed to move new therapies more quickly into the development pipeline

Mascoma Corporation

Mascoma Corporation Raises $30 Million in Series B Funding Led By General Catalyst Partners

Mascoma Corporation Raises $30 Million in Series B Funding Led By General Catalyst Partners

November 13, 2006

Leader in cellulosic biomass-to-ethanol development and production to continue research and development to make renewable fuel a sustainable reality for consumers

Flagship’s David Berry quoted in eBioNews in an article titled, “A New Bloom for Algae.”

Flagship’s David Berry quoted in eBioNews in an article titled, “A New Bloom for Algae.”

July 8, 2010

David Berry was recently interviewed for an article in eBioNews outlining efforts over the last several years to utilize algae as a source for biofuels.

A New Bloom for Algae

Thursday, 08 July 2010 07:49

A DOE roadmap marks a return to research on a source of fuel that was once thought too costly.

Accuri Cytometers, Inc.

Accuri Cytometers Completes $6 Million Series E Financing

Accuri Cytometers Completes $6 Million Series E Financing

July 12, 2010

ANN ARBOR, Mich., July 12 /PRNewswire/ -- Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.

Joule Unlimited, Inc.

Joule Names John Ward Senior Vice President of Production

Joule Names John Ward Senior Vice President of Production

July 20, 2010

Cambridge, Mass. – July 20, 2010 – Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today announced the appointment of John Ward as Senior Vice President of Production, overseeing the company's scale-up planning, direction and construction as it advances towards commercial production of solar-derived, renewable fuels and chemicals. This will include management of Joule’s site selection and related partnerships with CO2 emitters to drive Joule's process, as well as assisting in the deployment of commercialization partners' production facilities.

TARIS Biomedical, Inc.

TARIS Appoints Sarma Duddu as President and CEO

TARIS Appoints Sarma Duddu as President and CEO

July 19, 2010

Accomplished Pharmaceutical Executive

Lexington, MA – July 19, 2010 – TARIS Biomedical , a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced that Sarma Duddu, Ph.D. has been named President and Chief Executive Officer and a member of the Board of Directors, effective immediately.

Novomer, Inc.

Novomer Selected for DOE Grant

Novomer Selected for DOE Grant

July 22, 2010

Secretary Chu Announces Six Projects to Convert Captured CO2 Emissions from Industrial Sources into Useful Products

$106 Million Recovery Act Investment will Reduce CO2 Emissions and Mitigate Climate Change

Tetraphase Pharmaceuticals, Inc.

TetraPhase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections

TetraPhase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections

November 24, 2006

Company Completes $25M Series A Financing

Watertown and Cambridge MA, November 24, 2006 - TetraPhase Pharmaceuticals Inc. and Harvard University’s Office of Technology Development (OTD) announced today the formation of a biotechnology company that will develop new classes of antibiotics aimed at drug-resistant infections. The Company’s approach capitalizes on ground-breaking technology and patents licensed from Harvard University.

Adnexus Therapeutics

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

November 28, 2006

Accomplished Drug Development Physician to Drive Clinical Advancement of Maturing Adnectin™ Product Pipeline

Waltham, MA, November 28, 2006 – Adnexus TherapeuticsTM today announced the expansion of its management team with the appointment of Bruce A. Silver, MD, FACP to the newly-created role of Medical Director. The advancement into Phase 2 of CT-322, the company’s lead product that is currently in Phase 1 development in oncology, will be among Dr. Silver’s responsibilities.